Personalized care in Radiation Oncology

During the first six years of its operations, RTsafe has focused mainly on brain cancer. PseudoPatient, nominated as one of the 100 most technologically significant products in 2019, is the personalized care solution that RTsafe has developed, patented and commercialized for brain tumor patients, following extensive R&D and tens of scientific publications. It is a 510k-FDA cleared solution that is already contributing to the safety and effectiveness of radiotherapy treatments globally – in a totally personalized way.

Our next core milestones are to make our personalized quality assurance solutions easily accessible to millions of cancer patients globally and to keep innovating and developing equivalent solutions for cancer types other than brain tumors.

At RTsafe, our goal is to develop and implement high-end technologies to achieve maximum treatment efficiency combined with maximum patient safety, allowing the patient to return to life’s activities, following an effective treatment.

Whatever role you play in the treatment cycle, RTsafe’s products and services can help you. Click on the button below to learn more about the benefits we can bring to you and your colleagues.

Find out how RTsafe can help you

Lorem Ipsum is simply dummy text of the printing and typesetting industry.

Learn how our technology changes the way
you work.

Lorem Ipsum is simply dummy text of theprinting and typesetting industry.

Learn how our technology changes the way
you work.

Lorem Ipsum is simply dummy text of theprinting and typesetting industry.

Learn how our technology changes the way
you work.

The PseudoPatient® solution

Play Video

See what's new at RTsafe

RTsafe to exhibit at ESTRO 2023 in Vienna

RTsafe to exhibit at ESTRO 2023 in Vienna

Conferences - Tradeshows
The annual congress of ESTRO will take place 12-16 May 2023 in Vienna, Austria. ESTRO offers the radiation oncology community the chance...
Read More
RTsafe announces first use of its PseudoPatient patient-specific quality assurance process by Fundación Instituto Valenciano de Oncología (IVO)

RTsafe announces first use of its PseudoPatient patient-specific quality assurance process by Fundación Instituto Valenciano de Oncología (IVO)

Announcements
  Athens, Greece, February 13, 2023   RTsafe, the leading provider of quality assurance products and services in stereotactic radiosurgery, announces that...
Read More
National Funding for the RTsafe project AVATAR

National Funding for the RTsafe project AVATAR

Announcements
We are thrilled to share that the Horizon2020 RTsafe project AVATAR, which received a Seal of Excellence from the European...
Read More

Testimonials

Download our complete
product cataloque.

Request a quote

End Users

Customers Placeholder
Customers
ΕΣΠΑ Banner